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AntioxidantsOxidative stress-related renal pathologies apparently include rhabdomyolysis and ischemia/reperfusion
phenomenon. These two pathologies were chosen for study in order to develop a proper strategy for
protection of the kidney. Mitochondria were found to be a key player in these pathologies, being both the
source and the target for excessive production of reactive oxygen species (ROS). A mitochondria-targeted
compound which is a conjugate of a positively charged rhodamine molecule with plastoquinone (SkQR1) was
found to rescue the kidney from the deleterious effect of both pathologies. Intraperitoneal injection of SkQR1
before the onset of pathology not only normalized the level of ROS and lipid peroxidized products in kidney
mitochondria but also decreased the level of cytochrome c in the blood, restored normal renal excretory
function and signiﬁcantly lowered mortality among animals having a single kidney exposed to ischemia/
reperfusion. The SkQR1-derivative missing plastoquinone (C12R1) possessed some, although limited
nephroprotective properties and enhanced animal survival after ischemia/reperfusion. SkQR1 was found to
induce some elements of nephroprotective pathways providing ischemic tolerance such as an increase in
erythropoietin levels and phosphorylation of glycogen synthase kinase 3β in the kidney. SkQR1 also
normalized renal erythropoietin level lowered after kidney ischemia/reperfusion and injection of a well-
known nephrotoxic agent gentamicin.of Physico-Chemical Biology,
kulachev),
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Acute renal injury (ARI) in critically ill patients is highly associated
with poor prognosis, and despite the increasing efforts to alleviate
fatal consequences of ARI, the mortality rate among these patients
remains a severe problem [1–3]. Moreover, not only ARI itself but also
extrarenal complications accompanying or predisposing to ARI often
result in multiorgan failure and greatly contribute to the fatality of a
kidney malfunctioning [4,5]. In general, current strategies to treat ARI
or its consequences include four principal methods. The most
common and widespread method is hemodialysis, which is based
on the artiﬁcial, external removal of harmful wastes and excess salt
and ﬂuids from the blood. Another approach includes the induction of
natural mechanisms of cell protection such as modulation of the
immune system or ischemic preconditioning. The third approach uses
pharmacologic intervention to prevent or alleviate the deadly effects
of ARI. And ﬁnally, when all three listed approaches fail, the only
option remains a kidney transplant. Without going into the details ofthese four lines of treatment for ARI, we conclude that all four are still
very costly, complicated, and inconvenient while often resulting in an
imperfect outcome. However, pharmacologic treatment of ARI and
associated pathologies has demonstrated appreciable progress and
has potential that has yet to be exhausted. For example, where certain
kidney pathologies can be attributed to the consequences of oxidative
stress, antioxidant treatment is an attractive approach. Thus, in a great
number of cases, patients with kidney failure due to these pathologies
may potentially beneﬁt from exposure to antioxidants when carefully
and wisely used [6–11], reviewed in Koyner et al. [12].
Mitochondria-targeted antioxidants have been developed to
provide speciﬁc delivery of antioxidant molecules to the interior of
the mitochondrion, which potentially suffers from oxidative stress
more than other cellular compartments. The chimeric molecule of
such an antioxidant in principle contains a cation, bearing delocalized
charge to allow movement into the mitochondrial matrix conjugated
with an antioxidantmoiety (e.g., coenzyme Q10 [13] or plastoquinone
[14,15]). The proton motive force existing in the inner mitochondrial
membrane becomes the driving machinery for a transport of these
cationic antioxidants into mitochondria, thus achieving a drug
concentration 10,000 times higher in the mitochondrial matrix than
in the cytosol [13–16]. The beneﬁcial effect of these compounds has
been demonstrated in a number of cell pathologies, although the
mechanism of cell protection remains poorly understood [13,16–21].
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compounds either carrying an antioxidant moiety or without it as a
potential agent to efﬁciently alleviate the deleterious consequences of
ARI arising from two distinct pathologies, both of which apparently
involve oxidative stress: kidney ischemia/reperfusion (I/R) and
rhabdomyolysis (also called myoglobinuria or crush syndrome as a
speciﬁc case of rhabdomyolysis). Spontaneous myoglobinuria is
caused by necrotic degradation of striated muscles, resulting in the
appearance of the muscle protein myoglobin in the bloodstream with
subsequent kidney dysfunction. In earlier studies we [22,23] and
others [24] demonstrated the key role of mitochondria as a source and
a target of oxidative stress and apparent involvement of the
mitochondrial permeability transition in both pathologies. Particu-
larly, we demonstrated that myoglobin supplementation to kidney
tubules caused apparent oxidative stress evidenced by a rise in ROS
level in the tubules and signiﬁcant loss of the mitochondrial
transmembrane potential [23]. For kidney I/R, we have also identiﬁed
some features of endogenous protective pathways against tissue
damage caused by this intervention involving the beneﬁcial role of the
inhibition of glycogen synthase kinase-3 (GSK-3). To facilitate the
future design of directed pharmacologic interventions to normalize
renal function subsequent to ARI, we explored the underlying
mechanisms of nephroprotection and the role of mitochondria in
these two pathologies using a positively charged membrane-perme-
able, mitochondrial-targeted compounds carrying an antioxidative
moiety [15] or without it [25]. These compounds, named SkQR1 and
C12R1, have structures presented in Fig. 1. In an earlier study [26], we
have shown that injection of SkQR1 results in a drop of blood
creatinine level elevated under I/R and experimental rhabdomyolysis.
These ﬁndings demanded to run a comprehensive study to explore in
detail the nephroprotective potential of mitochondria-targeted drugs
under ARI.2. Materials and methods
2.1. Modeling of glycerol-induced rhabdomyolysis in rats
Experiments were performed on outbred white male rats (180–
200 g) fed ad libitum. Animal protocols were approved by the
institutional review boards. Rats were anesthetized with sodium
pentobarbital (50 mg/kg, intraperitoneal). Rhabdomyolysis was in-
duced by a standard method by injection of 10 ml/kg of 50% water
solution of glycerol (ICN, USA) into the legmuscles of rats as described
earlier [27]. Control animals were untreated. The therapeutic protocol
of SkQR1 used to treat this pathology was next: i/p injection ofFig. 1. The chemical structure of SkQR1 (a chimericmolecule combining amitochondria-
targeting rhodamine derivative with plastoquinone, a plant-derived antioxidant) and
C12R1 representing SkQR1 without quinone moiety.100 nmol/kg SkQR1 1 hr after induction of rhabdomyolysis with
subsequent injections at 13, 25, and 37 hrs; in total, each rhabdo-
myolytic animal received 400 nmol/kg SkQR1. On the second day after
the injection, blood samples were taken and kidneys were excised for
the mitochondria isolation with further determination of malondial-
dehyde in the tissue and mitochondria. Blood creatinine and urea
concentrations were determined using the CellTac blood analyzer. The
rhabdomyolysis model experiments were performed with at least
eight animals in each group.
2.2. Ischemia/reperfusion protocol
The animals were subjected to 40-min warm ischemia of the left
kidney as described in Plotnikov et al. [26]. Brieﬂy, unilateral renal
arteries were clamped by a microvascular clip for 40 min, and then
circulation was restored by removing the clip. Nephrectomy of the
right side was executed together with ischemia. During operation, the
body temperature of the rat was maintained at 37±0.5 °C using a
thermoregulatory heating unit connected to a rectal probe. On the
second day after ischemia blood samples were taken to determine
creatinine and urea concentrations using a CellTac blood analyzer
(Nihon Kohden Corp., Japan). The therapeutic protocol of SkQR1
treatment: i/p injection of 100 nmol/kg SkQR1 3 hrs before I/R, 1 hr
after I/R, and subsequent injections at 13, 25, and 37 hrs; in total, each
animal received 500 nmol/kg SkQR1. Sham-operated rats were used
as controls. Rats were allocated into the following groups: (1) sham
(n=12), (2) I/R+saline (n=12), (3) I/R+SkQR1 (n=12).
2.3. Renal histology
The kidney was isolated immediately after sacriﬁcing the animal
andwashedwith ice-cold phosphate-buffered saline. It was then ﬁxed
in a 10% neutral buffered formalin solution, embedded in parafﬁn and
used for histopathological examination. Five micrometer thick
sections were cut, deparafﬁnized, hydrated, and stained with
hematoxylin and eosin. The renal sections were examined in blinded
fashion for tubular necrosis, hemorrhagic and hyaline casts in the
kidneys of all treated animals. A minimum of 10 ﬁelds for each kidney
slide were examined and scored for pathologic severity. A score from
0 to 4 was given for each pathological sign (necrosis, casts and
dilatation): 0, normal histology; 1, from 5% to 25% of tubules have
pathology; 2, moderate damage, from 25% to 50% of tubules have
pathology; 3, severe, from 50% to 75% have pathology; and 4, almost
all tubules in ﬁeld of view are damaged. The average histological score
for each sample was calculated.
2.4. Gentamicin nephrotoxicity protocol
Animals were randomly divided into two groups, each containing
6 animals. The ﬁrst group (GM-group) of rats received gentamicin
intraperitoneally in a single daily dose of 150 mg/kg. The second
(GMS-group) of rats received SkQR1 intraperitoneally in a daily dose
of 100 nmol/kg 3 h before gentamicin in the same dose as in G-group.
Animals in the third (C-group), serving as a negative control, received
saline 1 ml/d intraperitoneally. All groups were treated over a period
of 6 consecutive days. Following the last application, all animals were
sacriﬁced, and the kidneys were subsequently removed for Western
blotting analysis.
2.5. Experiments with renal tubular epithelium cell cultures and kidney
slices
Kidneys were excised aseptically from 3- to 7-day-old rats, then
homogenized and placed in balanced Hank's solution at pH 7.4. After
several washes, the dispensed tissue was placed in 0.1% collagenase
and incubated for 20–30 min at 37 °C. Large pieces were removed, and
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pellet was resuspended in DMEM/F-12 1:1 containing 10% fetal calf
serum (FCS) and seeded in culture plates and glass-bottom dishes.
Cells were cultivated in a CO2 (5%) incubator for 1–2 days before the
experiments. The myoglobin solution was added to the cultured
epithelial cells to a ﬁnal concentration of 500 μMand incubated for 1 h
at 37 °C in DMEM/F-12 medium containing 10 mM HEPES–NaOH.
Next, cells were washed to remove residual myoglobin and incubated
with the ROS-sensitive ﬂuorescent probe 2′,7′-dichlorodihydroﬂuor-
escein diacetate (DCF-DA, 10 μM; Invitrogen, USA). The SkQR1,
mitochondrial-targeted antioxidant was added to the cultured
epithelial cells to a ﬁnal concentration of 250 nM and incubated for
24 h before myoglobin addition.
Renal cortex tissue slices 200 μm thick were cut with a VibroSlice
microtome (World Precision Instruments) and placed into Hank's
solution containing 10 mM HEPES–NaOH at pH 7.4 with an appro-
priate concentration of DCF-DA.
2.6. Confocal microscopy
Experiments were carried out at 37 °C except where otherwise
indicated. Kidney slices and renal tubular epithelial cells were washed
to remove residual DCF-DA and imaged with an LSM510 inverted
confocal microscope (Carl Zeiss Inc., Jena, Germany). Analysis of
ﬂuorochrome incorporation was performed in glass-bottom dishes
with excitation at 488 nm and emission collected at 500–530 nm. To
minimize the contribution of photo-induced mitochondria/cell dam-
age to the relative ﬂuorescence intensities, image analysis was
performed on the average of the ﬁrst four scans only. Images were
processed using ImageJ software (NIH, Bethesda, MD, USA).
2.7. Isolation of mitochondria from rat kidney
Kidney mitochondria were isolated by homogenization and
differential centrifugation in a medium containing 250 mM sucrose,
20 mM HEPES–KOH, 1 mM EGTA, and 0.1% BSA at pH 7.4. Total
mitochondrial protein was determined using a bicinchoninic acid
protein assay kit (Sigma Aldrich, USA).
2.8. Measurement of MDA products
Malondialdehyde production in kidney tissue homogenates was
explored by a conventional colorimetric method with the use of the
malondialdehyde–thiobarbituric acid reaction according to Mihara
and Uchiyama [28]. Brieﬂy, each mitochondrial sample was mixed
with 0.8% thiobarbituric acid and 1% H3PO4 in the ratio by volume
0.9:1.0:3.0. The mixture was boiled for 45 min, cooled to room
temperature and then centrifuged at 15,000×g for 10 min. Absor-
bance of the resulting supernatant at 532 nm was measured using a
Hitachi 557 spectrophotometer. 1,3,3-tetraetoxipropan (Sigma, USA)
was used as a calibration standard. The content of malondialdehyde
found was ﬁnally normalized by total protein content.
2.9. Western blot analysis
Samples of serum or tissue homogenates were loaded onto 15%
Tris–glycine polyacrylamide gels at a concentration of 50 μg total
protein per lane. After electrophoresis, gels were blotted onto PVDF
membranes (Amersham Pharmacia Biotech, UK). Membranes were
blocked with 3% (wt./vol.) non-fat milk in PBS with 0.1% (vol./vol.)
Tween 20 and subsequently incubated with primary antibodies:
mouse monoclonal anti-cytochrome c 1:1000 (BD Biosciences
Pharmingen, USA), rabbit polyclonal anti-erythropoietin 1:1000
(Santa Cruz Biotechnology Inc., USA), mouse monoclonal anti-P-
GSK-3β 1:1000 (Cell Signaling, USA), mouse monoclonal anti-total-
GSK-3β 1:1000 (Cell Signaling, USA), mouse monoclonal anti-porin1:1000 (BD Biosciences Pharmingen, USA). Membranes were then
stained with secondary antibodies: anti-mouse IgG or anti-rabbit IgG
conjugated with horseradish peroxidase 1:30000 (Calbiochem, USA).
Detection of antibody binding was achieved using the ECL Plus
Western blotting kit (Amersham Pharmacia Biotech, UK). After
scanning, the density of the resulting staining was measured for
each band using ImageJ software (NIH, Bethesda, MD, USA).
2.10. Statistics
All experiments were performed at least in triplicate. All data are
presented as mean±SEM. Comparisons between groups were made
using a Student t test with a P value less than 0.05 taken to indicate
statistical signiﬁcance.
3. Results
3.1. SkQR1 rescues kidney function from the deleterious effects of
myoglobinuria
We examined myoglobinuria as the model of oxidative insult
affecting kidney function. When myoglobin was administered to
cultured renal epithelial cells, these cells displayed the same signs of
oxidative stress, namely the mitochondrial membrane potential, as
evaluated by uptake of the mitochondrial dye TMRE, decreased (not
shown) while the production of ROS in the cells, as indicated by DCF
ﬂuorescence, increased (Figs. 2A and B). The exact colocalization of
ROS and mitochondrial dye (not shown) demonstrates that as in the
case of I/R [22], mitochondria become a source of such induced ROS
production. The pretreatment of the cells with SkQR1 (250 nM) 1 day
prior to myoglobin administration alleviates oxidative stress induced
by myoglobin.
In another model of myoglobin-induced oxidative stress in the
kidney, we used intramuscular injection of glycerol to induce muscle
degradation and the release of myoglobin into the bloodstream.
Exploration of the dynamics of the resulting rhabdomyolysis-induced
acute renal failure showed that within 2 days after injection, blood
creatinine and BUN reached their maximum levels, indicating critical
renal failure [23]. The therapeutic protocol of SkQR1 used to treat this
pathology was next: i/p injection of 100 nmol/kg SkQR1 1 hr after
induction of rhabdomyolysis with subsequent injections at 13, 25, and
37 hrs; in total, each rhabdomyolytic animal received 400 nmol/kg
SkQR1. Earlier we have demonstrated partial normalization of serum
creatinine after SkQR1 treatment [26]. Similarly, the level of BUN in
the serum of rhabdomyolytic animals demonstrated about a 7-fold
increase; after SkQR1 treatment, it was lowered by about 2-fold
(Fig. 3A). Simultaneously, the excessive generation of malondialde-
hyde in the tissue (Fig. 3B) and in isolated kidney mitochondria (not
shown) caused by myoglobinuria was almost fully reversed by SkQR1
injection after induction of rhabdomyolysis. C12R1 having no
antioxidant moiety possessed some although limited nephroprotec-
tive properties (Fig. 3A).
Cytochrome c, probably originating from the breakdown of tissues,
has been observed in the blood serum of rhabdomyolitic animals
[23,29]. This important marker of rhabdomyolitic degradation of the
kidney was used in our study to evaluate the severity of kidney
damage during myoglobinuria. Figs. 3C and D demonstrate that rats
treated with SkQR1 before myoglobinuria exhibited signiﬁcantly
lower levels of serum cytochrome c than untreated rhabdomyolitic
animals, suggesting that SkQR1 pretreatment alleviated rhabdomyo-
litic damage to the tissues.
3.2. Ischemia/reperfusion of the kidney induces oxidative stress
In our previous study, we demonstrated the key role of mitochon-
drial dysfunction in kidney damage after I/R [22]. In this study, we
Fig. 2. Evidence of higher ROS production in renal tubular cells exposed to myoglobin. (A) Confocal microscopy of cultured tubular cells stained with DCF-DA. Control cells did not
show any visible DCF ﬂuorescence. After incubation with 500 μM myoglobin (MB) for 1 hr, DCF ﬂuorescence increased signiﬁcantly; quantitative results are shown in B.
Preincubation with 250 nM SkQR1 24 hrs prior to myoglobin addition (MB+SkQR1) results in signiﬁcantly lower DCF ﬂuorescence in response to myoglobin administration.
80 E.Y. Plotnikov et al. / Biochimica et Biophysica Acta 1812 (2011) 77–86conﬁrmed earlier observation that ROS production, as detected by DCF
ﬂuorescence in vital cortex sections, was signiﬁcantly higher in kidneys
exposed to I/R as compared to controls (Figs. 4A and B). Digital analysis
of ﬂuorescence intensity in confocal images showed that DCF
ﬂuorescence proﬁles were colocalized with mitochondria stained with
mitochondrial dye [22], demonstrating that mitochondria are respon-
sible for the ROS burst caused by I/R. This rise in ROS level apparentlyFig. 3. Indices of kidney dysfunction during rhabdomyolysis and the rescue effect of SkQR1
induction of rhabdomyolysis in the plasma of control, rhabdomyolitic (Rhabdo), SkQR1-treat
(MDA) in the kidney homogenates of the same groups. (D) Average intensity of the spots sho
C12R1 injections (100 nmol/kg each) were made 1, 18, 30, and 42 hrs after induction of rhprovoked dramatic changes in lipid structure. Fig. 4C demonstrates that
I/R resulted in a signiﬁcant elevation of the kidney tissue content of
malondialdehyde, suggesting the induction of lipid peroxidation. As we
demonstrated previously [18], 1 μmol/kg SkQR1 injected 24 hrs before
ischemia prevented elevation of DCF signal in a renal tissue. In the
current study, both ROS burst and higher level of tissue malondialde-
hyde were signiﬁcantly attenuated by pretreatment of rats with much. Concentrations of (A) blood urea nitrogen (BUN) and (C) cytochrome c 24 hrs after
ed (Rhabdo+SkQR1) and C12R1-treated (Rhabdo+C12R1) rats. (B) Malondialdehyde
wn in C for all experimental groups; 6 blots for 6 different rats were evaluated. SkQR1 or
abdomyolysis. *pb0.005 and **pb0.01.
Fig. 4. Confocal microscopy of vital sections from rat kidney cortex stainedwith DCF-DA (A). Kidneys were taken from untreated rats (Control) and rats subjected to 40-min ischemia
and 10-min reperfusion (I/R) with or without 100 nmol/kg SkQR1 injected 3 hr prior to ischemia. (B) Quantitation of DCF ﬂuorescence in A. Five different sections for each
experimental group were evaluated along 10 different ﬁelds counted in each section. (C) Malondialdehyde (MDA) content in kidney tissue measured 2 days after ischemia. SkQR1
injections (100 nmol/kg each) were made 3 hrs prior to ischemia and 1, 18, 30, and 42 hrs after ischemia. *pb0.005 and **pb0.01.
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exposure time (100 nmol/kg injected once 3 hrs before ischemia,
Figs. 4B and C).
3.3. SkQR1 lowers the mortality of single-kidney rats exposed to I/R
In the experiments on survival of animals subjected to renal insult,
we applied a more severe model of ischemic insult by removing one
kidney as was suggested by Dobashi et al. [30] and further extendedFig. 5. Blood urea nitrogen (BUN) in control plasma (Control in A and C) and in plasma from r
treatment (I/R+SkQR1). (A) SkQR1 and C12R1 injections (100 nmol/kg each) were made
(100 nmol/kg each) were made 1, 13, 25, and 37 hrs after ischemia. (B and D) Mortality a
without (squares) and with SkQR1 treatment (triangles): (B) SkQR1 (triangles) and C12R1 (
and 42 hrs after ischemia; (D) SkQR1 injections (100 nmol/kg each) were made 1, 18, 30, aby Serviddio et al. [31]. In this model, kidney I/R in animals that
underwent right nephrectomy caused a dramatic rise in blood
creatine [26] and urea nitrogen (BUN) and induced the death of the
majority of experimental animals (Figs. 5A and B). The injection of
either SkQR1 or C12R1 prior to ischemia and during the reperfusion
phase signiﬁcantly lowered creatinine [26] and BUN and drastically
increased the survival of animals (Figs. 5A and B). When SkQR1 was
injected only during the reperfusion period, normalization of the
kidney function following ischemia did not occur (see BUN level inats subjected to 40-min ischemia and 48 hrs of reperfusion (I/R) with or without SkQR1
3 hrs prior to ischemia and 1, 13, 25, and 37 hrs after ischemia; (C) SkQR1 injections
mong rats having a single kidney and exposed to unilateral ischemia and reperfusion
circles) injections (100 nmol/kg each) were made 3 hrs prior to ischemia and 1, 18, 30,
nd 42 hrs after ischemia. *pb0.005 and **pb0.01.
Fig. 6. Effects of SkQR1 on ischemia- and glycerol-induced rhabdomyolysis-induced pathological features in renal morphology. Images show kidney sections stained with
hematoxylin and eosin. (A) Control kidney. (B) Kidney excised 2 days after 40-min warm ischemia. Kidney tubules are observed with apparent focal necrosis of epithelial cells
(shown by arrows) and noticeable dilatation (black arrowheads). (C) SkQR-treated kidney excised 2 days after 40-min warm ischemia. (D–F) Kidney of control rats and excised
2 days after induction of rhabdomyolysis. Necrotic kidney tubules (white arrows) are shown. Bar, 50 μm.
Table 1
Effects of SkQR1 on ischemia- and glycerol-induced rhabdomyolysis-induced renal pathological features.
Ischemia/reperfusion Rhabdomyolysis
Control IR IR+SkQR1 Control Rhabdo Rhabdo+SkQR1
Necrosis 0 2.21±0.08 0.60±0.02 0 3.8±0.3 2.8±0.25
Protein casts 0.05±0.02 1.00±0.15 1.27±0.2 0.05±0.02 1.2±0.1 0.8±0.05
Dilatation 0 2.21±0.2 1.47±0.15 N/A N/A N/A
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untreated ones) within 3–4 days, critical for animals with right
nephrectomy exposed to I/R (Fig. 5D).
It is worth mentioning here that SkQR1 under the concentration
used (100–1000 nmol/kg) did not have any inﬂuence on renal
functioning of intact animals: diuresis, the amount of products of
nitrogen metabolism, reabsorption ability of tubules, and glomerular
ﬁltration rate were not changed neither on 1st nor on 4th day after
SkQR1 injection. In addition, moderate hepatotoxic effect of SkQR1 in
a dose of 1 μmol/kg has been found on day 1 after injection expressed
in slight elevation of blood AST and ALT.Fig. 7. Changes in renal erythropoietin (EPO) and phosphorylated glycogen synthase kinase-
kidney tissue. Representative Western blots with corresponding densitometry below the blo
the kidneys of 4 different rats. Band densities were normalized to the density of the α-tub
1 μmol/kg C12R1 was injected 24 hrs before excising the kidney; kidneys after I/R were analy
gentamicin+SkQR1 treatment were analyzed after 6 consecutive days of the treatment. *p
treated with 250 nM SkQR1 for 24 hrs (H). (G) Untreated cells. (I and J) Confocal micrograph
with 1 μmol/kg SkQR1 for 24 hrs.3.4. SkQR1 alleviates histopathological changes in a renal tissue
Histological study demonstrated changes in kidney morphology
induced by both I/R and rhabdomyolysis consistent with those
described elsewhere [8,10]. The changes observed in the kidney
exposed to 40 min of warm ischemia in a single-kidney rat appear to
indicate severe tubular necrosis (Fig. 6B versus control in A) and mild
casts formation (Table 1). In the cortex, the tubules with fully necrotic
cells are evident. Outside of these areas, the tubules did not show
visible morphological effects. The morphological ﬁndings of dilatation
of proximal tubules are suggestive of an obstructive lesion. Rats3β (P-GSK-3β) levels. (A–F) Detection of EPO (A, C, E, F) and P-GSK-3β (B, D) in the total
ts are shown. The densitometry results represent an average over 6 blots obtained from
ulin band. 1 μmol/kg SkQR1 was injected i/p 3 and 24 hrs before excising the kidney;
zed 2 days after I/R with or without SkQR1 treatment. Kidneys after gentamicin (GM) or
b0.01. (G and H) Immune reactivity to anti-EPO Ab of cultured kidney epithelial cells
s of rat kidney slices stained with anti-EPO Ab: (I) control kidney and (J) kidney treated
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damage (Fig. 6C). SkQR1 treatment lowered the number of necrotic
tubules and dilatation of tubules and resulted in practically normal
histological appearance but did not affect the casts' formation
(Table 1).
Rhabdomyolytic rat kidneys demonstrated marked pathological
features in the cortex and outer medulla. The renal sections showed
severe tubular necrosis (Fig. 6E) as well as hyaline and hemorrhagic
casts (Table 1). Rats treated with SkQR1 yielded kidney sections
showing much less pronounced tubular necrosis (Fig. 6F), but the
number of hyaline and hemorrhagic casts was almost the same as in
untreated rats (Table 1).
3.5. SkQR1 provides some elements of ischemic tolerance
In the experiments presented above, we observed the signiﬁcant
nephroprotective properties of a mitochondria-targeted compound,
SkQR1. To gain insight into the mechanisms of nephroprotection
afforded by SkQR1, we measured the concentrations of two
components of anti-ischemic defense signaling systems, speciﬁcally
erythropoietin (EPO) and GSK-3β. Single i/p injection of SkQR1
(1 μmol/kg) caused 80% rise of EPO level in the kidney after 3 hrs and
about 100% elevation after 24 hrs (Figs. 7A and J) while the level of
phosphorylated GSK-3β (enzymatically inactive form) reached 120%
and 200% of baseline 3 and 24 hrs after injection of SkQR1,
respectively (Fig. 7B). Remarkably, we detected the induction of
EPO production in primary culture of rat kidney cells 24 hrs after
incubationwith 250 nM SkQR1 (Figs. 7G and H). Single i/p injection of
C12R1 (1 μmol/kg) did not change EPO and phospho-GSK-3 level in a
renal tissue after 24 hrs (Figs. 7C and D). When elements of intrinsic
protective pathways were analyzed, we found that 2 days after I/R,
EPO production in kidney was signiﬁcantly decreased versus control
animals, whereas after I/R with SkQR1 treatment, renal EPO content
was similar to control (Fig. 7E).
In addition, we ran experiments with antibiotic gentamicin known
for its nephrotoxicity as a side effect when applied. We observed a
signiﬁcant drop of EPO level in a total kidney tissue after 6 days of
gentamicin treatment, with restoration of EPO level after 100 nmol/kg
SkQR1 was injected daily 3 hrs before gentamicin (Fig. 7F).
4. Discussion
The unique ability of the mitochondrion to build H+ transmem-
brane potential for supporting ATP synthesis was recently exploited to
create drugs targeted to mitochondria. The design of these drugs is
based on the use of a construct containing a hydrophobic part carrying
positive charge delocalized over a number of coupled double bonds
which can be driven into mitochondria and considered as a
locomotive [13–16]. The linker locomotive part of the molecule is
bound to another component carrying the function, which is in
demand. In the SkQR1 molecule shown in Fig. 1, the locomotive
moiety, a derivative of rhodamine 19, is bound via a linker to a natural
antioxidant of plant origin, plastoquinone [14]. This chimeric
compound by design was intended to quench the excessive
production of ROS in mitochondria. Experiments showed that this
compound is easily permeable through the inner mitochondrial
membrane and must be distributed in mitochondrial matrix consid-
ering the presence of the transmembrane potential over the inner
mitochondrial membrane (about 150–180 mV, negative inside) and
the potential existing over cellular membrane (about 50–60 mV,
negative inside) [14,15,21]. Taken together, these potentials result in a
driving force for cation electrophoresis leading to concentrations of
the cationic substance about 10,000 times higher than in the
extracellular milieu. If one accounts for the high hydrophobicity of
this compound, this concentration gradient will be even higher,
implying that intramitochondrial content of this compoundwill be onthe order of millimolars when it is administered to the blood or
extracellular ﬂuid at submicromolar concentrations.
By design, a potential mitochondrial-targeted drug should dem-
onstrate very powerful antioxidative properties inside the mitochon-
dria under conditions of oxidative stress. Since mitochondria are
known to be one of the major players in oxidative stress of any origin,
the treatment of oxidative stress-related pathologies with compounds
like this may be highly beneﬁcial. Speciﬁcally, since a great number of
renal pathologies involve oxidative stress, mitochondria-targeted
antioxidant drugs should ameliorate renal damage in these
pathologies.
In the present study, surgical ischemia/reperfusion of the kidney as
well as myoglobin and glycerol-induced experimental rhabdomyo-
lysis were used as models to test whether SkQR1 can prevent or cure
ARI. Both pathologies are known to greatly contribute to the onset of
acute renal failure with no known effective pharmacologic means of
prevention.
Ischemia followed by reperfusion is a common pathological trigger
for the kidney damage considering the high vulnerability of this organ
to the transitions, which occur during cessation and restoration of
blood ﬂow [32]. Renal injury associated with I/R is a general cause of
acute renal failure as has been observed after renal transplantation,
shock, sepsis, and renal artery stenosis. Several pharmacological
therapies have been proposed to treat renal pathologies associated
with I/R. The most efﬁcient options at present include the adminis-
tration of antioxidants and antioxidative systems, nitric oxide and
nitric oxide synthase inhibitors, EPO, peroxisome proliferator-acti-
vated receptor agonists, inhibitors of poly(ADP-ribose) polymerase,
carbon monoxide releasing molecules, statins, adenosine, and others
[33].
Mitochondria suffer from I/R as much as other intracellular
components. I/R-induced mitochondrial fragmentation, as observed
in cultured kidney cells [34] as well as in kidney tissue [22], is a prime
example of mitochondrial morphological rearrangement preceded,
accompanied or followed by functional changes expressed in an
inability to maintain energy-producing and transducing functions. As
a result of ischemic insult, mitochondria are transformed from the
organelles producing signaling (protecting) levels of ROS to those
producing excessive (pathology-inducing) ROS, apparently by the
mechanism known as ROS-induced ROS release [35,36].
Another model of a renal mitochondria-mediated oxidative stress
is rhabdomyolysis which is also related to I/R [27,37,38]. Nowadays,
rhabdomyolysis is considered one of the major causes of acute renal
failure. People usually develop rhabdomyolysis after crush injuries
produced by events such as earthquakes, mine collapses, trafﬁc or
working accidents, wounding, various intoxications, and many other
reasons. Usually, patients have vague symptoms such as swollen
extremities and muscle weakness but up to one third of them will
develop kidney failure [37]. Sometimes to save a life the affected limb
must be amputated.
The most widely used experimental model of rhabdomyolytic
acute renal failure involves the subcutaneous or intramuscular
injection of hypertonic glycerol, which causes myolysis similar to
that caused by traumatic muscle compression followed by the release
of muscle content into the bloodstream culminating in tubular
necrosis and acute renal failure [39].
Heme-containing proteins or their degradation products, includ-
ing ionic iron released from damaged muscle, have been found to
display tubular nephrotoxic properties partially mediated by the
generation of reactive oxygen and nitrogen species [23,39,40].
Our ﬁndings strongly demonstrate that the attenuation of
mitochondria-mediated oxidative stress in the kidney signiﬁcantly
improves renal function. The speciﬁc mitochondria-targeted antiox-
idant SkQR1 was found to offset and alleviate the consequences of
myoglobinuria and renal I/R. The severity of renal damage in
rhabdomyolysis was higher than in the case of ischemia/reperfusion.
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rhabdomyolysis is less expressed and it had almost no effect on cast
formation (described in Fig. 6 and Table 1). Apparently, the striated
muscle damage and myoglobin release in the bloodstream under
rhabdomyolysis are SkQR1-independent especially as its injection has
been made after rhabdomyolysis induction. Thus, SkQR1 might not
have the effect on cast formation; however, it does have a strong
inﬂuence on further events, namely on the myoglobin-induced
oxidative stress. We conclude that as a result of SkQR1 action,
oxidative stress goes down in parallel with a drop of renal cell death.
So, although SkQR1 cannot prevent accumulation of Mb in renal
tissue, it ameliorates damaging consequences of this accumulation,
thus ﬁnally lowering AKI.
In the case of ischemic damage, the primary cause of AKI is
oxidative stress induced by internal factors, namely by enhanced ROS
generation in mitochondria [22]. In this case, SkQR1 acts directly on
the level of mitochondrial ROS so it protects kidney cells more
effectively, which is expressed in a lower number of necrotic tubules
(see Table 1).
Given that myoglobinuria and renal I/R are among the most
widespread and damaging renal pathologies, the renoprotective effect
of this compound potentially can be used in the therapy of I/R-related
pathologies including rhabdomyolysis.
Importantly, SkQR1was found to be able to exert protective effects
not only through direct scavenging of ROS (which seems reasonable
considering its very high ﬁnal intramitochondrial concentration) but
also by providing the kidney with elements of ischemic tolerance
signaling mechanisms. We detected two key elements induced by
administration of SkQR1, namely EPO and the phosphorylated form of
GSK-3β. EPO is known to possess pleiotropic properties distinct from
its well-known hematopoietic activity [41–44] that afford protection
against ischemic damage (reviewed in Sharples and Yaqoob [45]). The
activity of GSK-3β is inversely related to the phosphorylation status of
serine-9 in this enzyme while its dephosphorylation results in
activation of the kinase [46]. Prosurvival signals were shown to
correlatewith the presence of the phosphorylated form of GSK-3β and
protective signaling pathways converge via inhibition of GSK-3β on
the end effector, the permeability transition pore complex, preventing
the induction of the mitochondrial permeability transition [47].
Remarkably, apart from its direct antioxidative potential, SkQR1 can
upregulate protective signaling mechanisms to afford protection not
only in the kidney but also possibly in the heart and brain [26].
Remarkably, some, although limited, protective properties were
found for C12R1, bearing no antioxidative moiety in the molecule.
Suchmodiﬁcation of the SkQR1molecule resulted in a loss of ability to
induce synthesis of EPO in the kidney. It gives strong evidence that,
namely antioxidative moiety of SkQR1 molecule is responsible for the
induction of signaling pathways providing ischemic tolerance. C12R1-
afforded limited protection of the kidney we explain by indirect
induction of defense pathway independent on that with EPO involved.
Proven protonophorous activity of C12R1 in planar phospholipid
membranes and liposomes [42] may be a clue to consider the role of
this drug in protective mechanisms through mild uncoupling of
mitochondria. Mitochondrial mild uncoupling was shown to result in
a signiﬁcant decrease in the rate of ROS formation by mitochondria,
providing a tolerance to oxidative stress-induced pathologies [48].
Interestingly, there is a tight link between tissue EPO level and the
speciﬁc activity of GSK-3β. Speciﬁcally, it has been shown that EPO
administration stimulates the production of phosphorylated GSK-3β
in the heart [49,50] and the kidney [51] (our unpublished data),
demonstrating the synergy between these two signals. It is notewor-
thy that 3 hrs after SkQR1 administration, we could observe a rise in
EPO concentration in the kidney cells while the level of phosphory-
lated GSK-3β was almost unchanged (Fig. 7B). Finally, after 24 hrs of
administration of SkQR1, an increase in the level of phosphorylated
GSK-3β was detected (Fig. 7B), illustrating an apparent delayedcausative effect of the tissue level of ROS on GSK-3β phosphorylation.
SkQR1 also normalized renal EPO level dropped after kidney I/R and
injection of a well-known nephrotoxic agent gentamicin. This
indicates the central role of the kidney EPO synthesis in the realization
of SkQR1-mediated nephroprotection.
There is evidence that general antioxidants can induce the
generation of EPO in cells [52,53]. It seems plausible that during
treatment with the mitochondria-targeted antioxidant SkQR1, direct
antioxidative effects and induction of ischemic preconditioning
signaling pathways are linked in synergy due to the targeted delivery
of this compound to mitochondria.
We conclude that SkQR1 affords renal protection under different
pathologic conditions with some limitations speciﬁc for each
pathology. These limitations cover the non-toxic concentration
range used and the time frame of SkQR1 application in order to
afford effective protection.5. Disclosure
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